Pieris Pharmaceuticals, Inc.

PIRS

US7207952026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
11.72 ^USD	+1.03%		+1.03%	-19.51%

Apr. 19	Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement	MT
Apr. 03	North American Morning Briefing : Powell Awaited -2-	DJ

Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index

June 23, 2023 at 12:00 am EDT

Latest news about Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals Shares Fall After 1-for-80 Reverse Stock Split Announcement	Apr. 19	MT
North American Morning Briefing : Powell Awaited -2-	Apr. 03	DJ
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief	Jan. 05	MT
North American Morning Briefing : Stocks Seen -2-	Nov. 15	DJ
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
North American Morning Briefing : Stock Futures -2-	Nov. 08	DJ
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from S&P Global BMI Index	23-09-18	CI
Vicore Pharma's New CEO to Formally Take Office	23-09-08	MT
Sweden’s Hansa Biopharma Appoints New Chief Scientific Officer	23-09-01	MT
Pieris Pharmaceuticals Says Patient Dosing in Cancer Drug Trial Triggers Milestone Payment From Boston Pharmaceuticals	23-08-17	MT
North American Morning Briefing : Treasury Yields -2-	23-08-17	DJ
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
North American Morning Briefing : Attention Turns -2-	23-08-10	DJ
Pieris to Cut 70% Workforce, Hires Advisor For Strategic Review; AstraZeneca to End R&D Deal	23-07-18	MT
Pieris Pharmaceuticals to Explore Strategic Options	23-07-18	CI
Pieris Pharmaceuticals, Inc. Announces Executive Changes	23-07-13	CI
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell Microcap Growth Index	23-06-23	CI
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell Microcap Index	23-06-23	CI
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Index	23-06-23	CI
Pieris Pharmaceuticals, Inc.(NasdaqCM:PIRS) dropped from Russell 3000E Growth Index	23-06-23	CI
Sector Update: Health Care Stocks Steady to Higher Late Wednesday	23-06-21	MT
Sector Update: Health Care	23-06-21	MT
Top Midday Decliners	23-06-21	MT

Chart Pieris Pharmaceuticals, Inc.

Duration

Period

More charts

Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Companyâs clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
PIERIS PHARMACEUTICALS, INC.	-19.51%	14.35M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.37%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.85%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.86B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.04B

Bio Therapeutic Drugs